D. Boral Capital initiated coverage of Cero Therapeutics (CERO) with a Buy rating and $11 price target The company’s proprietary platform, ...

The T-cell receptor (TCR) therapy landscape has been comprehensively detailed, showcasing a promising future for this innovative treatment approach by 2025. Advancements within TCR therapy are ...

Complete the form below to unlock access to ALL audio articles.

Join us for the second annual Cell and Gene Therapy online symposium, where expert speakers will discuss the current therapeutic landscape, covering ground-breaking research in cancer immunotherapy, ...

The therapy is a thyroid hormone receptor beta ... s role in managing NASH and potentially influencing the future landscape of metabolic disease treatment,” they concluded.

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...

Through its advanced technologies for ready-to-use products, Cellistic is transforming the cell therapy landscape, enabling efficient and accessible treatment options that meet industry demands.